title: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
abstract: OBJECTIVE
  To evaluate the safety and maximum-tolerated dose (MTD) of weekly patupilone, a natural epothilone B, in patients with advanced solid tumors.
  
  
  METHODS
  Patients were treated with patupilone (0.3 to 3.6 mg/m2) for 6 weeks on/3 weeks off or 3 weeks on/1 week off. Dose-limiting toxicities (DLTs), MTD, and pharmacokinetics were determined for each schedule of administration.
  
  
  RESULTS
  Ninety-one patients were enrolled. The most common tumor types included ovarian, breast, and colon cancers. Doses of patupilone less than 2.5 mg/m2 using either the 6 weeks on/3 weeks off or the 3 weeks on/1 week off schedule were tolerated well. At higher doses, DLTs were observed using both dosing schedules, with diarrhea the most common DLT. The MTD for both treatment schedules was 2.5 mg/m2. After a short infusion, patupilone blood concentrations declined in a multiphasic manner with a terminal half-life of 4 days. Drug clearance was nonrenal and was not related to body-surface area. Over the dose range evaluated, systemic drug exposure was approximately dose proportional. Three patients achieved a partial response, and 31 patients had stable disease. Two patients experiencing a partial response had received prior taxane therapy.
  
  
  CONCLUSIONS
  Patupilone is well tolerated when administered at a dose of 2.5 mg/m2, using either a 6 weeks on/3 weeks off or a 3 weeks on/1 week off schedule. In contrast with murine studies, patupilone has a relatively prolonged terminal half-life in humans. The partial responses in patients previously treated with taxanes is consistent with promising preclinical results.
authors.affiliation: Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA. ehrubin@umdnj.edu
authors.forename: Eric H
authors.initials: EH
authors.lastname: Rubin
authors.forename: John
authors.initials: J
authors.lastname: Rothermel
authors.forename: Fisseha
authors.initials: F
authors.lastname: Tesfaye
authors.forename: Tianling
authors.initials: T
authors.lastname: Chen
authors.forename: Martine
authors.initials: M
authors.lastname: Hubert
authors.forename: Yu-Yun
authors.initials: YY
authors.lastname: Ho
authors.forename: Chyi-Hung
authors.initials: CH
authors.lastname: Hsu
authors.forename: Amit M
authors.initials: AM
authors.lastname: Oza
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D034261:Epothilones / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D034261:Epothilones; C093788:epothilone B